- Conditions
- Schizophrenia Spectrum and Other Psychotic Disorders, Schizophrenia, Delusional Disorder, Bipolar 1 Disorder, Schizoaffective Disorder, Psychosis Not Otherwise Specified, Early Psychosis
- Interventions
- Not listed
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Other
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 320 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 6
- States / cities
- Hartford, Connecticut • Athens, Georgia • Chicago, Illinois + 3 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–32
of 8
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Schizophrenia Disorders
- Interventions
- Placebo (single and multiple doses), AQW051 2 mg (single and multiple doses), AQW051 15mg (single and multiple doses), AQW051 100mg (single dose), and 50mg (multiple doses)
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 2
- States / cities
- Glendale, California • Willingboro, New Jersey
- Conditions
- Late Onset Schizophrenia, Delusional Disorder (Late Onset)
- Interventions
- Tau PET imaging scan
- Diagnostic Test
- Lead sponsor
- Jeremy Koppel
- Other
- Eligibility
- 65 Years to 85 Years
- Enrollment
- 16 participants
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Manhasset, New York
- Conditions
- Parkinson Disease
- Interventions
- Pimavanserin
- Drug
- Lead sponsor
- State University of New York - Downstate Medical Center
- Other
- Eligibility
- 40 Years to 85 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Brooklyn, New York
- Conditions
- Alzheimer's Disease Psychosis
- Interventions
- ACP-204
- Drug
- Lead sponsor
- ACADIA Pharmaceuticals Inc.
- Industry
- Eligibility
- 55 Years to 95 Years
- Enrollment
- 752 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 21
- States / cities
- Costa Mesa, California • Fresno, California • Garden Grove, California + 8 more
- Conditions
- Parkinson's Disease Psychosis, Dementia With Lewy Bodies
- Interventions
- Pimavanserin, Quetiapine
- Drug
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- Not listed
- Enrollment
- 94 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 2
- States / cities
- San Antonio, Texas
- Conditions
- Major Depressive Disorder With Psychotic Features
- Interventions
- Olanzapine, Sertraline, placebo
- Drug · Other
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 259 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2008
- U.S. locations
- 3
- States / cities
- Worcester, Massachusetts • New York, New York • Pittsburgh, Pennsylvania
- Conditions
- Schizophrenia, Schizoaffective Disorder, Delusional Disorder
- Interventions
- Not listed
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 14 Years to 50 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2003 – 2016
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania